Goldman Sachs Group Inc. Buys 83,919 Shares of SiBone $SIBN

Key Points

• Goldman Sachs Group Inc. increased its stake in SiBone by 28.4% in Q1, owning approximately 0.89% of the company worth $5.3 million.
• Recent trading activity includes significant insider sales, with Director John Gordon Freund selling over 12,000 shares and insider Anthony J. Recupero selling nearly 3,900 shares.
• SiBone's stock is down 3.6%, currently trading at $15.14, while the company reported an earnings per share of ($0.14), beating expectations.

Goldman Sachs Group Inc. increased its stake in SiBone (NASDAQ:SIBN - Free Report) by 28.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 379,757 shares of the company's stock after buying an additional 83,919 shares during the period. Goldman Sachs Group Inc. owned 0.89% of SiBone worth $5,328,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. ANTIPODES PARTNERS Ltd bought a new stake in shares of SiBone during the 1st quarter valued at $34,000. Virtus Fund Advisers LLC bought a new position in shares of SiBone during the fourth quarter valued at approximately $40,000. GAMMA Investing LLC boosted its stake in SiBone by 20,352.6% in the first quarter. GAMMA Investing LLC now owns 3,886 shares of the company's stock valued at $55,000 after acquiring an additional 3,867 shares in the last quarter. Virtus Advisers LLC purchased a new position in shares of SiBone in the first quarter worth $58,000. Finally, Johnson Investment Counsel Inc. purchased a new position in shares of SiBone in the first quarter worth $148,000. Institutional investors own 98.11% of the company's stock.

Wall Street Analysts Forecast Growth

SIBN has been the subject of several recent research reports. Cantor Fitzgerald set a $25.00 target price on shares of SiBone and gave the stock an "overweight" rating in a report on Monday, August 11th. Wall Street Zen cut shares of SiBone from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $23.67.

Insider Buying and Selling at SiBone

In other SiBone news, SVP Michael A. Pisetsky sold 3,329 shares of the business's stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $15.64, for a total transaction of $52,065.56. Following the sale, the senior vice president owned 258,352 shares in the company, valued at approximately $4,040,625.28. The trade was a 1.27% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Laura Francis sold 11,343 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $15.60, for a total transaction of $176,950.80. Following the completion of the sale, the chief executive officer directly owned 419,704 shares of the company's stock, valued at $6,547,382.40. This trade represents a 2.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 46,590 shares of company stock valued at $765,137. 4.00% of the stock is currently owned by insiders.

SiBone Trading Down 3.8%

NASDAQ SIBN traded down $0.58 during mid-day trading on Friday, hitting $14.60. The company's stock had a trading volume of 825,770 shares, compared to its average volume of 313,574. SiBone has a 52-week low of $11.70 and a 52-week high of $20.05. The stock's fifty day simple moving average is $16.31 and its two-hundred day simple moving average is $16.34. The company has a debt-to-equity ratio of 0.21, a current ratio of 8.38 and a quick ratio of 7.00. The firm has a market capitalization of $629.84 million, a P/E ratio of -26.07 and a beta of 0.81.

SiBone (NASDAQ:SIBN - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.05. The business had revenue of $48.63 million during the quarter, compared to analyst estimates of $48.12 million. SiBone had a negative net margin of 12.83% and a negative return on equity of 14.20%. SiBone has set its FY 2025 guidance at EPS. Research analysts expect that SiBone will post -0.78 EPS for the current year.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.